<DOC>
	<DOCNO>NCT00343798</DOCNO>
	<brief_summary>This phase I multicenter feasibility trial study safety potential efficacy infuse ex vivo expand cord blood progenitor one unmanipulated umbilical cord blood unit transplantation follow condition fludarabine , cyclophosphamide total body irradiation ( TBI ) , immunosuppression cyclosporine mycophenolate mofetil ( MMF ) patient hematologic malignancy . Chemotherapy , fludarabine cyclophosphamide , TBI give umbilical cord blood transplant stop growth leukemia cell work prevent patient 's immune system reject donor 's stem cell . The healthy stem cell donor 's umbilical cord blood help patient 's bone marrow make new red blood cell , white blood cell , platelet . It may take several week new blood cell grow . During period time , patient increase risk bleed infection . Faster recovery white blood cell may decrease number severity infection . Studies show count likely recover quickly increase number cord blood cell give transplant . We develop way grow `` expand '' number cord blood cell lab cell available transplant . We study find whether give expanded cell along one unexpanded cord blood unit safe use expand cell decrease time take white blood cell recover transplant . We study time take blood count recover , two cord blood unit make patient 's new blood system , quickly immune system cell return</brief_summary>
	<brief_title>A Pilot Study Evaluate Co-Infusion Ex Vivo Expanded Cord Blood Cells With Unmanipulated Cord Blood Unit Patients Undergoing Cord Blood Transplant Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Examine safety toxicity ex vivo expand cord blood cell co-infused second non-human leukocyte antigen ( HLA ) -identical cord blood graft follow myeloablative therapy patient hematologic malignancy . II . Examine vivo persistence ex vivo expand cord blood cell . The kinetics durability hematopoietic reconstitution ( time engraftment define first 2 consecutive day absolute neutrophil count [ ANC ] &gt; 500 ) determine relative contribution engraftment expand cord blood cell unmanipulated cord blood cell early long-term engraftment determine donor chimerisms . SECONDARY OBJECTIVES : I . Estimate incidence severity acute chronic graft-versus-host disease ( GVHD ) patient receive Notch-expanded cord blood cell . II . Estimate incidence transplant related mortality day 100 . III . Estimate incidence malignant relapse probability overall event-free survival 1 2 year post transplant . IV . Obtain preliminary data phenotype function immune cell recover patient receive expand unmanipulated cord blood graft . V. Obtain feasibility data overnight shipment ex vivo expand progenitor cell infusion patient distant site . OUTLINE : MYELOABLATIVE CONDITIONING REGIMEN : Patients receive fludarabine intravenously ( IV ) 1 hour day -8 -6 cyclophosphamide IV day -7 -6 . Patients undergo TBI twice daily ( BID ) day -4 -1 . TRANSPLANTATION : On Day 0 , patient undergo double-unit umbilical cord blood transplantation include infusion one unmanipulated ( expand ) cord blood unit follow 4 hour later infusion one ex vivo-expanded cord blood unit . GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS : Patients initially receive cyclosporine IV begin day -3 . Cyclosporine may give orally patient tolerate oral medication normal gastrointestinal transit time . Cyclosporine give day 100 , may taper day 101 graft versus host disease . Patients also receive MMF IV day -3 5 may receive oral MMF begin day 6 30 . MMF stop Day 30 7 day engraftment , whichever day later , acute GVHD . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patient exist 01 HLAA , B , C , DRB1 DQB1 match related donor Acute Myeloid Leukemia : High risk first complete remission ( CR1 ) evidence precede myelodysplastic syndrome ( MDS ) , high risk cytogenetics ( example , monosomy 5 7 , HR define refer institution treatment protocol ) , &gt; = 2 cycle obtain complete remission ( CR ) , erythroblastic megakaryocytic leukemia ; &gt; = second complete remission ( CR2 ) ; All patient must CR define hematologic recovery &lt; 5 % blast morphology within bone marrow cellularity &gt; = 15 % ; Patients adequate marrow/biopsy specimen obtain determine remission status morphologic assessment , fulfil criterion remission flow cytometry ( &lt; 5 % blast ) , recovery peripheral blood count circulate blast , may still eligible ; reasonable attempt must make obtain adequate specimen morphologic assessment , include possible repeat procedure Acute lymphoblastic leukemia : High risk CR1 ( example , limit : ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) mixedlineage leukemia ( MLL ) rearrangement , hypodiploid ) ; &gt; 1 cycle obtain CR ; &gt; = CR2 ; All patient must CR define hematologic recovery &lt; 5 % blast morphology within bone marrow cellularity &gt; = 15 % ; Patients adequate marrow/biopsy specimen obtain determine remission status morphologic assessment , fulfil criterion remission flow cytometry ( &lt; 5 % blast ) , recovery peripheral blood count circulate blast , may still eligible ; reasonable attempt must make obtain adequate specimen morphologic assessment , include possible repeat procedure Chronic Myelogenous Leukemia : Patients blast crisis ( BC ) must receive therapy must achieve accelerate phase ( AP ) /chronic phase ( CP ) order eligible ( patient remain BC eligible ) ; If first chronic phase , patient must fail intolerant imatinib mesylate Myelodysplasia ( MDS ) : International Prognostic Scoring System ( IPSS ) Int2 high risk ( Refractory anemia excess blast [ RAEB ] , refractory anemia excess blast transformation [ RAEBt ] ) refractory anemia severe pancytopenia high risk cytogenetics ; Blasts must &lt; 10 % morphologically representative bone marrow aspirate ( obtain &lt; 2 week enrollment ) Lymphoblastic lymphoma , Burkitt 's lymphoma , highgrade nonHodgkin lymphoma ( NHL ) initial therapy stage III/IV first partial remission ( PR1 ) progression stage I/II &lt; 1 year ; Stage III/IV patient eligible progression complete response ( CR ) /partial response ( PR ) Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma , lymphoplasmacytic lymphoma follicular lymphoma progress least two different prior therapy ; patient bulky disease ( nodal mass great 5 cm ) consider debulking chemotherapy transplant ( patient must present Patient Care Conference [ PCC ] prior enrollment give potential compete eligibility autotransplant protocol ) Mantlecell lymphoma , prolymphocytic leukemia : Eligible initial therapy &gt; = CR1 &gt; = PR1 Large cell NHL &gt; CR2/ &gt; PR2 : Patients CR2/PR2 initial short remission ( &lt; 6 month ) eligible ; These patient must present PCC prior enrollment give potential compete eligibility autotransplant protocols Multiple myeloma beyond PR2 : Patients chromosome 13 abnormality , first response last less 6 month , beta2 microglobulin &gt; 3 mg/L , may consider protocol initial therapy Serum creatinine = &lt; 2.0 mg/dL ( adult ) creatinine clearance &gt; 60 ml/min ( pediatrics ) Patients clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , histology , degree portal hypertension ; patient fulminant liver failure , cirrhosis evidence portal hypertension bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , correctable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL symptomatic biliary disease exclude Diffusing capacity lung carbon monoxide correct ( DLCOcorr ) &gt; 50 % normal Left ventricular ejection fraction &gt; = 45 % shorten fraction &gt; 26 % Karnofsky score &gt; = 70 % ( adult ) Lansky score &gt; = 50 % ( pediatrics ) Acute leukemia relapse ( &gt; = 5 % marrow blast morphology ) Active central nervous system ( CNS ) leukemia involvement time study enrollment ( cerebrospinal fluid &gt; 5 white blood cell ( WBC ) /mm^3 AND malignant cell cytospin ) Chemotherapy refractory large cell lymphoma high grade NHL ( progressive disease &gt; 2 salvage regimen ) Female patient pregnant breastfeed Karnofsky performance status &lt; 70 % ( adult ) Lanksy score &lt; 50 % ( pediatrics ) Prior autologous allogeneic stem cell transplant myeloablative preparative regimen ( If = &lt; 18 year old , prior myeloablative transplant within last 6 month ) Uncontrolled viral , bacterial infection time study enrollment Active recent ( prior 6 month ) invasive fungal infection without ID consult approval Seropositive human immunodeficiency virus ( HIV ) Consenting 5 6 6 6 HLAmatched relate donor available Unable provide inform consent Use experimental drug within 28 day baseline</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>